Navigation Links
Big data analysis identifies prognostic RNA markers in a common form of breast cancer
Date:4/29/2013

COLUMBUS, Ohio A Big Data analysis that integrates three large sets of genomic data available through The Cancer Genome Atlas has identified 37 RNA molecules that might predict survival in patients with the most common form of breast cancer.

The study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) initially analyzed messenger RNA (mRNA) and microRNA expression, DNA methylation data and clinical findings for 466 patients with invasive ductal carcinoma, the most common type of breast cancer.

The analysis identified 30 mRNAs and seven microRNAs short snippets of RNA that were consistently associated with patient outcome across 44 clinical and molecular subclasses, including early-stage tumors. The researchers then validated the prognostic signature using genome-wide expression data from 2,399 breast-cancer patients in eight independent groups and found that it performed better than other RNA signatures currently used for breast-cancer risk stratification.

The findings are published in the Proceedings of the National Academy of Sciences.

"This is the first prognostic signature in breast cancer or other type of cancer that combines both mRNA and microRNA," says first author and researcher Dr. Stefan Volinia, associate professor of molecular virology, immunology and medical genetics at the OSUCCC James, "and we believe this concise RNA signature could prove useful for the clinical management of breast-cancer patients."

Principal investigator Dr. Carlo M. Croce, professor of molecular virology, immunology and medical genetics, and director of Human Cancer Genetics, notes that most of the genes involved in the RNA signature have not previously been linked to breast cancer and that unlike many other prognostic signatures, this one does not contain genes involved in the cell cycle or tumor grade.

"Most of these prognostic genes are newcomers, and therefore they might represent novel drug targets," says Croce, who is also the John W. Wolfe Chair in Human Cancer Genetics. "They also are novel genes with unknown function and need further study."

He noted that these genes could also be candidates for a blood test for early detection.

Key points related to the study's findings include:

  • The identified RNA signature might predict response to treatment, as well as being prognostic;

  • DNA methylation was used to confirm the association between mRNA expression and overall survival;

  • The signature includes mutations in PIK3CA and its pathway, indicating that the PIK3CA/AKT2/PTEN axis is an important and independent cofactor in prognosis;

  • The prognostic value of the integrated signature was highest in early stage I and II breast cancers, making this a potentially valuable biomarker signature in clinical practice.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related biology news :

1. Turtle genome analysis sheds light on the development and evolution of turtle-specific body plan
2. Predicting the next eye pathogen; analysis of a novel adenovirus
3. Satellite sandwich technique improves analysis of geographical data
4. Market Analysis: Biomaterials and Engineered Protein
5. Genetic analysis saves major apple-producing region of Washington state
6. Genetic analysis calls for the protection of 2 highly endangered Portuguese fish species
7. Eurofins MWG Operon and Queen Mary, University Of London commence genome sequencing analysis of Ash
8. Temp-controlled nanopores may allow detailed blood analysis
9. Biomass analysis tool is faster, more precise
10. Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals
11. Scientists publish analysis of algae parasite impact on algae biofuel in PLOS ONE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... Del. (PRWEB) , ... July 08, 2019 , ... ... Court ruled in favor of Danisco’s ownership of the innovation behind two Danisco ... that an entitlement action could be based on prior art was without merit ...
(Date:6/25/2019)... ... , ... ActX has launched a medical genetic interpretation ... can get access to professionally reviewed genetic screening similar to what a physician ... + Ancestry customers., With the ActX + 23andMe service, both 23andMe customers and ...
(Date:6/19/2019)... LAS VEGAS (PRWEB) , ... June 19, 2019 , ... ... on improving physicochemical properties of Cefazolin Sodium, antibiotic which can prove to be beneficial ... Over 519% increase in residue amount , Over 68% decrease in ...
Breaking Biology News(10 mins):
(Date:6/26/2019)... ... June 26, 2019 , ... Alice Branton today released research results from preclinical ... Magnesium Gluconate, which can prove to be beneficial for treating Hypomagnesemia. , The preclinical ... change in crystallite size , Over 142% increase in particle size , ...
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology Ltd is pleased ... Biofeedback Tech Ltd as its authorised distributor for the UK and ... therapeutic treatments and clinical assessment protocols to treat stress related disorders as well ...
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative ... Inc. (PSC) , has announced that their GMP facility for cell production is ... for manufacturing. This is an important milestone for VetStem as it expands ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. The ... TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. The ...
Breaking Biology Technology: